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Abstract
Background: Q fever caused by Coxiella burnetii is transmitted to humans by inhalation of aerosols from animal
birth products. Q fever in pregnancy is suspected to be a potential cause of fetal and maternal morbidity and fetal
mortality but the pathogenesis is poorly understood, and even in Q fever endemic areas, the magnitude of a
potential association is not established.
We aimed to examine if presence of antibodies to C. burnetii during pregnancy or seroconversion were associated
with adverse pregnancy outcomes.
Methods: The Danish National Birth Cohort collected blood samples and interview data from 100,418 pregnant
women (1996–2002). We sampled 397 pregnant women with occupational or domestic exposure to cattle or sheep
and a random sample of 459 women with no animal exposure. Outcome measures were spontaneous abortion,
preterm birth, birth weight and Small for Gestational Age (SGA).
Blood samples collected in pregnancy were screened for antibodies against C. burnetii by enzyme-linked
immunosorbent assay (ELISA). Samples positive for IgG or IgM antibodies in the ELISA were confirmed by
immunofluorescence antibody test (IFA).
Results: Among the 856 women, 169 (19.7%) women were IFA positive; 147 (87%) of these had occupational or
domestic contact with livestock (IFA cutoff > =1:128).
Two abortions were IFA positive vs. 6 IFA negative (OR: 1.5; 95%CI: 0.3-7.6). Three preterm births were IFA positive
vs. 38 IFA negative (OR: 0.4; 95% CI: 0.1-1.1). There was a significant difference in birth weight of 168 g (95% CI: 70-
267 g) with IFA positive being heavier, and the risk of being SGA was not increased in the newborns of IFA positive
women (OR: 0.4; 95%CI: 0.8-1.0).
Most seropositive women were IgG positive indicating previous exposure. Seroconversion during pregnancy was
found in 10 women; they all delivered live babies at term, but two were SGA.
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Conclusion: We found no increased risk of adverse pregnancy outcome in women with verified exposure to C.
burnetii.
To our knowledge, this is the first population-based seroepidemiologic study evaluating pregnancy outcome in
women with serologically verified exposure to C. burnetii against a comparable reference group of seronegative
women.
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Background
Q fever is a zoonotic infection caused by Coxiella
burnetii, an intracellular pathogen. In small ruminants Q
fever is known to cause abortions, retained placenta,
endometritis and infertility. Placentas of infected animals
contain high numbers of bacteria [1,2]; the bacteria re-
main viable for months in the environment.
Human infection is usually acquired through inhal-
ation of contaminated aerosols from infected animals
that contaminate the environment in particular through
excretion of the bacteria in large amounts in birth-by
-products, especially placenta [3-5].
Q fever has previously been considered a rare, im-
ported infection in Denmark, but recent studies have
found antibodies against C. burnetii in a large percent-
age of Danish dairy cattle as well as in humans exposed
to livestock [6-8].
For otherwise healthy people, Q fever infection is often
asymptomatic or has a mild, flu-like course, but may also
cause severe pneumonia. Pregnant women, immunocom-
promised patients and patients with pre-existing cardiac
valve- or vascular defects are at risk of a severe course of
infection [3,5].
Q fever in pregnancy is suspected to be a potential
cause of fetal morbidity and mortality, but the pathogen-
esis is poorly understood, and even in Q fever endemic
areas the magnitude of a potential association is not
established.
Present evidence mainly originates from French case
studies of referred infected pregnant patients in which
untreated infection was followed by spontaneous abor-
tion, intrauterine growth retardation, oligohydramnion,
stillbirth or premature delivery [9]. Infection in preg-
nancy is often asymptomatic but may imply an increased
risk of chronic infection and a risk of reactivation of a
past infection in subsequent pregnancies has been
suggested [9-11].
Two new studies evaluated infection in pregnancy and
found no increased risk of adverse pregnancy outcome
in seropositive pregnancies [12,13].
Although Q fever is endemic worldwide, the reported
prevalence seems to be highest in areas with medical or
scientific awareness of the infection and many obste-
tricians know little about the infection [10]. Since the
evidence of pregnancy outcome in women with Q fever
infection relies primarily on case reports, unbiased esti-
mates of the risks of adverse pregnancy outcome among
infected women remain largely unknown.
Our primary objectives were to evaluate the asso-
ciation between antibodies to C. burnetii and pregnancy
outcome and to compare pregnancy outcome in women




The study was based on interview data and blood
samples from the Danish National Birth Cohort (DNBC),
which is a nationwide cohort of 100,418 pregnant women
and their offspring.
Enrolment in the DNBC took place between 1996 and
2002. The women were recruited in connection with the
first antenatal visit to the general practitioner. Informa-
tion on variables reflecting exposures before and during
the early part of pregnancy was collected by means of a
computer assisted telephone interview scheduled around
gestational week 12. A second interview was scheduled
in week 30 (interview forms are available at the website
for the cohort).
During pregnancy, two blood samples were collected;
one between gestational weeks 6 to 12, the second in
gestational week 24. A sample was also drawn from the
umbilical cord.
The interviews were performed if the women were
reached within four phone calls, and if they agreed to
participate.
The interviews covered reproductive history, age,
smoking status, domestic contact to animals as well as
very detailed questions regarding occupational contact
to different animals.
A detailed description of the cohort can be found else-
where [14].
In women who participated in the first interview and
who also provided a blood sample (n = 95000) the study
population was defined as follows: Occupational contact
with livestock (n = 195), domestic contact with cattle or
sheep (n = 202) and a randomly selected sample with
no contact to livestock (n = 459). Blood samples from
Nielsen et al. BMC Infectious Diseases 2013, 13:87 Page 2 of 8
http://www.biomedcentral.com/1471-2334/13/87
these 856 women were analyzed for antibodies against
C. burnetii.
Pregnancy outcome was defined as:
Spontaneous abortion: fetal loss before 154 days
(22 weeks) after the first day of the last menstrual
period with gestational age estimated from the
participants’ self- reported last menstrual period.
Preterm delivery: delivery (live births and stillbirths)
between gestational weeks 22 + 0 days and 36 weeks +
6 days.
Small for gestational Age (SGA): for children born
from week 37 + 0 and onwards, SGA was defined as a
birth weight corresponding to the 10th percentile in
gram and below. Children with a birth weight above
the 10th percentile were used as reference group.
The relationship between serological status, birth weight
and gestational age, respectively, was also evaluated.
We also evaluated late induced abortions and stillbirth.
Detection of antibodies against C. burnetii
C. burnetii expresses two antigens, phase I and phase II.
When infected, phase II IgG and IgM antibodies are
elevated, and they may remain positive for months to
years. A large study from Australia and England found
that phase II IgG antibodies persisted after four and 12 -
years, respectively [15].
In acute Q fever, primarily antibodies against phase II
are raised, and titers are higher than antibodies against
phase I. As with most other infections, IgM antibodies
appear first.
In chronic forms of the disease, antibodies against
phase I are elevated.
In order to determine antibodies against C. burnetii,
we chose a two-step approach. First, all samples were
screened in a commercial enzyme-linked immunosorbent
assay (ELISA). Positive samples from the ELISA were
confirmed with an immunofluorescence antibody test
(IFA) which is considered to be gold standard when diag-
nosing Q fever.
The commercial ELISA kit were purchased from
Panbio (Queensland, Australia) (cat. no. E-QFB01G and
E-QFB01M) and used according to the manufacturer’s
instructions with minor modifications; due to low sam-
ple volume the samples were diluted differently from
what was prescribed in the instructions but the same di-
lution factors were used.
Samples which were positive for either IgG or IgM
antibodies in the ELISA were confirmed with an IFA test
from Focus Diagnostics (ca. no. IF0200G and IF0200M).
The test was performed according to the instructions
provided by the manufacturer, with the following minor
modifications: due to a low amount of sample material,
the diluted samples 1:10 from the ELISA were used to
further dilute the samples as described by the manufac-
turer. The effect of the dilution in the Panbio buffer was
tested prior to the use on patient samples and did not
show any influence on the results (results not shown).
A local cutoff adjusted to the Danish population has
been defined [16], including negative, equivocal and posi-
tive titers. When the ELISA positive samples in our study
were reanalyzed using IFA, a modified version of the Da-
nish cutoff was used. A sample was considered IFA posi-
tive when any of the phases were 1:128 or above.
For women without animal exposure, only the blood
sample from the first trimester was analyzed. In women
with contact to livestock, blood samples from the umbil-
ical cord or mid-pregnancy were analyzed initially (n =
361 women) and therefore seroconversion during preg-
nancy could be monitored.
In order to detect a possible seroconversion through-
out pregnancy, our strategy was to initially analyze the
last existing blood sample (for 79 women this was the
mid pregnancy sample and for 282 it was the umbilical
cord sample). If this sample was tested positive in
ELISA, the first blood sample from pregnancy week 12–
16 was analyzed using ELISA.
In order to select which of the ELISA positive samples
from the beginning of pregnancy were to be reanalyzed in
IFA, the following criteria had to be met: a change in ELISA
from negative in the beginning of pregnancy to positive in
the mid-pregnancy or umbilical cord sample or a doubling
in the adjusted ELISA OD-value throughout pregnancy.
In analyses of pregnancy outcome, women with sero-
conversion as well as women who were seronegative in
the midpregnancy or in the umbilical cord sample were
classified as seronegative.
All serological analyses were performed in a certified
laboratory at Statens Serum Institut, Denmark. Labora-
tory personnel were blinded for exposure status and
samples were always analyzed in the same batch of com-
mercial kits.
Statistical analysis
Associations between positive serology (IFA), spontan-
eous abortion, preterm birth and Small for Gestational
Age (SGA) were analyzed by logistic regression. The as-
sociation between gestational age at birth (which does
not follow a normal distribution) and positive IFA ser-
ology was tested using a non-parametric (Wilcoxon) test.
We examined the association between positive serology
(IFA), birth weight and gestational age for children born
at term, respectively, by fitting multiple linear regression
models.
Maternal age (<25 years, 25–34 years, 35+ years),
number of previous pregnancies (0, 1+) and smoking
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during pregnancy (0, 1–10, 11+ cigarettes per day) were
a priori selected as potential confounders.
All analyses were carried out using STATA statistical
software, version 11.
Women enrolled in the Danish National Birth Cohort
gave both verbal and written consent to participate.
The women gave permission to include interview infor-
mation, blood samples, and health information from
other registers in the Danish National Birth Cohort. This
study was approved by the Danish National Birth Co-
hort, the Danish Data Protection Board, and the Danish
Regional Scientific Ethical Committee.
Results
Among the 856 women, antibodies against C. burnetii
(IFA) were detected in 169, while 687 women were IFA
negative. The majority (87%) of the IFA positive women
had contact to livestock (Table 1).
IFA positivity
Among the 169 IFA positive women, 159 were positive
in IgG phase II; 73 of these were also IgG phase I posi-
tive, six were only IgG phase I positive. Seven women
were positive in IgM phase II, three in IgM phase I. For
six women, there was an overlap in positivity between
IgM and IgG phases. Hence, the participants’ serology
mainly indicated previous infections.
Maternal age was normally distributed and age at re-
cruitment was similar among IFA positive and IFA ne-
gative women (mean: 24.7 years (SD: 7.0) vs. mean:
23 years (SD 9.8)). There was no difference in the num-
ber of previous pregnancies between the two groups and
the IFA positive and IFA negative women were, on aver-
age, recruited at the same gestational age (11 weeks
1 day (SD 3.7) vs. 10 weeks 6 days (SD 3.6)). A higher
proportion of IFA negative were smokers. Seropositive
samples were mainly from women who had contact to
livestock during pregnancy or 3 months prior to becom-
ing pregnant (Table 1).
Serology and pregnancy outcome
We found no association between positive serology and
risk of spontaneous abortion (adjusted OR: 1.5; 95% CI:
0.3-7.6) or preterm birth (adjusted OR: 0.4; 95% CI:
0.1-1.1) (Table 2).
Infants born by seropositive mothers had a 0.9 day
older gestational age than infants born by seronegative
mothers, but this difference was not significant (p = 0.06,
Wilcoxon non-parametric test). The relation between
positive IFA serology and gestational age was also tested
in a multiple linear regression model which did not
change the results significantly (adjusted difference: 1.2 -
days; 95% CI: -0.4 days - +2.7 days, (Table 2)).
When evaluating the birth weight for all newborns,
there was a significant weight difference (168 g; 95% CI:
70-267 g) with the IFA positive babies being heavier;
results were similar when restricting analyses to term
babies (37 completed weeks or more): (134 g; 95% CI:
47-221 g) (Table 3).
We found no association between SGA and seroposi-
tivity (IFA) (OR: 0.4; 95% CI: 0.8-1.0) (Table 3).
One IFA negative woman had an induced abortion
after pregnancy week 12 due to fetal disease. One pre-
term birth was a stillbirth in gestational week 23; two
women had stillbirths in gestational week 35, all were
IFA negative.
To further explore the relationship between contact to
livestock, seropositivity and pregnancy outcome, we also
examined the pregnancy outcome among IFA positive
women with livestock contact compared to IFA negative
women with no contact to livestock. We also compared
pregnancy outcome among IFA positive versus IFA
Table 1 Maternal characteristics of pregnant women
according to Q fever seropositivity in






<25 years 10 (5.9%) 94 (13.7%)
25 - <35 years 139 (82.3%) 492 (71.6%)
35 years+ 20 (11.3%) 101 (14.7%)
Prior pregnancies
0 57 (33.7%) 250 (36.4%)
1+ 112 (66.3%) 437 (64.6%)
Gestational age at recruitment:
<8 21 (12.4%) 111 (16.2%)
Week 8-12 86 (50.9%) 321(46.7%)
Week 12- < 16 38 (22.5%) 186 (27.1%)
Week 16+ 24 (14.2%) 69 (10.0%)
Smoking:
Non-smokers: 155 (91.7%) 566 (82.1%)
1- < 10 g/day 4 (2.4%) 64 (9.3%)
+10 g/day 8 (4.7%) 48 (7.0%)
Unknown 2 (1.2%) 9 (1.3%)
Animal Contact:
Occupational or domestic contact to
livestock (cattle, goats, sheep)
147 (87.0%) 250 (36.4%)
No contact to livestock 22 (13.1%) 437 (63.6)
Residence:
Living in rural area 121 (71.6%) 303 (44.5%)
Living in non-rural area 45 (26.6%) 373 (54.3%)
Unknown 3 (1.8%) 8 (1.2%)
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negative pregnant women within the groups of women
with livestock contact. None of the results showed any
significant association between seropositivity and ad-
verse pregnancy outcome (not shown).
Seroconversion and pregnancy outcome
A total of 14 women met the criteria for seroconversion
during pregnancy in ELISA. These were confirmatory
tested in the IFA; 10 of them seroconverted during preg-
nancy as defined by the modified Danish cutoff. All had
occupational or domestic contact to livestock. All gave
live birth at term, however, two newborns were SGA
(birth weight: 2110 g and 2236 g, respectively) (Table 4).
None of the seroconverters reported episodes of fever
during pregnancy at the interview by the beginning of
third trimester.
Discussion
We hypothesized that being seropositive in pregnancy
would be associated with adverse pregnancy outcome,
potentially mediated by reactivation of a latent infection
[9-11]. We also hypothesized that acute infection during
pregnancy would be related to adverse pregnancy out-
come. Neither of these hypotheses were confirmed as no
increased risk of adverse pregnancy outcome was found
in women with verified exposure to C. burnetii.
To our knowledge, this is the first population-based
seroepidemiologic study evaluating pregnancy outcome
in women with serologically verified exposure to C.
burnetii against a comparable reference group of sero-
negative women.
When diagnosing Q fever, a variety of serological
methods are available; the Panbio ELISA kit has previ-
ously been showed to be superior to other methods [18]
and suitable for large-scale screening [17,19]. The micro
immunofluorescence antibody test (IFA) is regarded as
the gold standard [20] because it is capable of determin-
ing both phase I and II antibodies simultaneously by the
use of two different antigens in a single sample. We have
previously demonstrated coherence between ELISA and
IFA [21].
Villumsen et al. established a national, very restrictive
cutoff in order to obtain a high specificity and a high
predictive value of a positive result [21]; this decision
was based on the assumption that Q fever was sporadic
in Denmark. However, particularly in rural populations
of Denmark, Q fever is more widespread than previously
considered [7,8] and one may now argue that the cutoff
may be too conservative.
Consequently, in the present study, we decided to use
a modified version of the Danish cutoff. A more conser-
vative interpretation of the serological values (theoretic-
ally leading to a lower positive prevalence and higher
Table 2 Gestational age parameters for Danish pregnant women according to antibodies against C.burnetii,
immunofluorescence antibody test (IFA)








Spontaneous abortion < 22 weeks (n = 8) 2 (1.2%) 6 (0.9%) OR: 1.4 1.5 (95% CI: 0.3–7.6)*
Preterm birth (< week 37) (n = 41) 3 (1.8%) 38 (5.5%) OR: 0.3 OR: 0.4 (95% CI: 0.1–1.1)**
Gestational age (>week 36 + 6) (n = 806****)
Median gestational age (interquartile range)
40 weeks 3 days
(39 w, 3d; 41 w,1 d)




1.2 days (−0.4– +2.7)**
*adjusted for age **adjusted for smoking, age and gravidity *** babies of IFA positive mothers were older **** of which 163 were seropositive and
643 seronegative.
Table 3 Birth weight parameters for Danish pregnant women according to antibodies against C.burnetii,









Birth weight all (n = 842) Median Birth weight
(interquartile range)
166 676 Mean difference
in gram*: 204 g
168 g (95% CI:70–267 g)**
3780 g (3480 g; 4085 g) 3600 g (3260 g; 3997 g)
Birth weight children born at term (n = 803***)
Median Birth weight (interquartile range)
163 640 Mean difference
in gram*: 160 g
134 g (95% CI: 47–221 g)**
3790 g (3490 g; 4090 g) 3650 g (3309 g; 4000 g)
Small for gestational age term pregnancies
(week 37+ (n = 82) Median Birth weight
(interquartile range)
9 73 OR: 0.5 0.4 (95% CI: 0.8–1.0)**
2820 g (2275 g; 3010 g) 2850 g (2350 g; 3030 g)
*IFA positive babies are heavier **adjusted for smoking, age and gravidity.
*** of which 163 were seropositive and 640 seronegative.
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predictive value) did not reveal any associations between
seropositivity and adverse outcome of pregnancy.
Finally, we also acknowledge that the cutoff applied in
our study is high compared with some other studies.
However, in a seroepidemiologic study including healthy
individuals, our priority was to maintain a high predict-
ive value for a positive result. The application of a lower
cutoff would have falsely classified additional women as
seropositive and lead to misclassification and thus a higher
risk of overlooking a potential association between (true)
seropositivity and adverse outcome of pregnancy.
Most of the seropositive women had markers of previ-
ous infections, but ten met the criteria for IFA serocon-
version. It is worth to note that two out of these women
gave birth to infants that were SGA. We cannot draw
any conclusions on the risk of adverse pregnancy out-
come from 10 cases and the low number of seroconverters
is a limitation to this study. Hence, we cannot make an in-
ference with respect to pregnancy outcome in women
with acute and, in particular, symptomatic infections.
The risk of reactivation of latent infection leading to
adverse pregnancy outcome has been reported [9,10].
However, the IgG positive women in our study had a
similar proportion of previous spontaneous abortions as
the seronegative women, and overall, reactivation of la-
tent infections leading to adverse pregnancy outcomes
was not observed in this population.
Detailed information on previous preterm births was
not available, and we chose adjustment for prior preg-
nancies regardless of pregnancy outcome.
In women with contact to livestock, we had the oppor-
tunity to evaluate seroconversion throughout pregnancy;
in women with no contact to livestock we only had
blood samples from beginning of the pregnancy. This
could potentially bias data as the women without animal
contact were assumed to be negative throughout preg-
nancy when, theoretically, they could be infected later in
their pregnancy. This is why women with seroconversion
as well as women who were seronegative in the mid-
pregnancy or in the umbilical cord sample were classi-
fied as seronegative in analyses of pregnancy outcome.
Also, stratified analysis on contact to livestock and preg-
nancy outcome (spontaneous abortion and preterm birth),
irrespective of titer status, showed no significant differ-
ence between the groups (results not shown).
A high seroprevalence of C.burnetii accompanied by
few clinical symptoms in farmers and veterinarians has
been found in Denmark as well as abroad [7,8,22]. We
evaluated pregnancy outcome in seropositive versus
seronegative women who had occupational, domestic, or
no exposure to livestock (as stated in the methods sec-
tion). The vast majority of the seropositive women were
exposed to animals (Table 1). Due to few unexposed, sero-
positive women we are unable to study adverse pregnancy
outcome in this group of women or clarify whether the
dynamics of infection differ in unexposed women com-
pared to women heavily exposed to C.burnetii.
The evidence of the impact of Q fever on pregnancy
outcome mainly originates from French case studies of
referred infected pregnant patients and pregnancies with
Q fever diagnosed retrospectively after an adverse preg-
nancy outcome [7,8]. The authors conclude that there is
a link between placentitis and obstetric complications.
However, in a recent study by Angelakis et al., [23] a
study of 30 pregnant women with acute infection in
pregnancy, no placentitis or isolation of C.burnetii is
found in 14 available biopsies. 17 of the women were
asymptomatic, but only two of these had an uncompli-
cated pregnancy illustrating the difficulty in segregating
harmless seroconversion from infection threatening
Table 4 Immunofluorescence antibody test (IFA) titres at beginning and end of pregnancy for the 10 seroconverted
pregnancies




















#1 Neg Neg Pos: 1:128 Neg Pos: 1:2048 Pos: 1:1024 Neg Neg 38 3190 g
#2 Neg Neg Neg Neg Pos: 1:256 Pos: 1:128 Neg Neg 38 4200
#3 Neg Neg Neg Neg Pos: 1:1024 Pos: 1:512 Neg Neg 42 2110 g
#4 Neg Neg Neg Neg Pos: 1:128 Pos: 1:128 Neg Neg 41 4220 g
#5 Neg Neg Neg Neg Pos: 1:128 Pos: 1:128 Neg Neg 41 3430 g
#6 Neg Neg Neg Neg Pos: 1:128 Pos: 1:128 Neg Neg 42 3400 g
#7 Neg Neg Neg Neg Pos: 1:128 Pos: 1:128 Neg Neg 40 3330 g
#8 Neg Neg Neg Neg Pos: 1:8192 Pos: 1:256 Neg Neg 39 2236 g
#9 Neg Neg Neg Neg Pos: 1:128 Pos: 1:128 Pos: 1:256 Pos: 1:128 40 3520 g
#10 Neg Neg Neg Neg Pos 1:512 Pos:1:128 Neg Neg 41 3950 g
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maternal and foetal health. In that study, genotyping
showed that QpDV plasmid was present in 4 of 7 C.
burnetii strains isolated from infected women with mis-
carriage. Apart from differences in study design, numbers
of pregnancies included, selection bias and cutoffs, the
disagreements between the French, the Dutch and our
studies could be related to strain specificity. Risk assess-
ment and management of Q fever in pregnancy may
therefore benefit from further clarification of the role of
strain differences and virulence factors.
The present study is subject to some limitations.
Due to the design of the study, it was not possible to
include early miscarriage as an outcome. Only few
participants were included prior to 8 weeks of gesta-
tional age (Table 1). It is possible that the study popula-
tion is biased towards a “healthy pregnant population”.
An increased risk in early pregnancy may in our study
be reflected by a “protective” effect in later pregnancy.
Also, maternal IgM cannot be detected in umbilical
cord blood, meaning that theoretically we could miss a
narrow window of acute infections in very late preg-
nancy with positive IgM but before IgG phase II eleva-
tion; the potential effect on pregnancy outcome from
this is, however, speculative.
The French recommendation regarding treatment with
cotrimoxazole throughout pregnancy in seropositive wo-
men [9,10,23] is widely practiced, but has recently been
questioned [24]. However, the number of acute infections
in our study is too small to impact these recommendations.
Overall, our findings are in line with two new studies
from The Netherlands, a country that recently saw the
world’s largest Q fever outbreak [25]. One study included
serum samples from early pregnancy of 1174 pregnant
women living in the high-risk area and found no associ-
ation between positive Q fever serology and adverse preg-
nancy outcome [13]. The other study was a randomized
controlled trial with 1229 women split into a screening
group and a control group; no difference in pregnancy
outcome was found between the two groups [12].
Conclusion
Seropositivity was not associated with adverse pregnancy
outcomes as this study did not find a higher risk of
spontaneous abortion, preterm birth, or low birth weight
among pregnancies positive for C. burnetii compared to
seronegative Danish pregnant women.
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